Blog
RSS FeedPosted by Michael Wonder on 26 Aug 2020
Knight and TherapeuticsMD announce Health Canada approval of Imvexxy
25 August 2020 - Knight Therapeutics and TherapeuticsMD announced today the approval of Imvexxy by Health Canada. In Canada, Imvexxy is ...
Posted by Michael Wonder on 20 Aug 2020
Health Canada grants market authorization for Tecentriq in combination with bevacizumab, the first immunotherapy combination treatment, for the most common form of liver cancer
19 August 2020 - Tecentriq in combination with bevacizumab improved overall survival and progression-free survival compared to the previous standard of ...
Posted by Michael Wonder on 19 Aug 2020
Dupixent (dupilumab injection) now approved by Health Canada for severe chronic rhinosinusitis with nasal polyposis
18 August 2020 - First biologic approved in Canada for adults with severe chronic rhinosinusitis with nasal polyposis. ...
Posted by Michael Wonder on 16 Aug 2020
Piqray is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR positive, HER2 negative advanced breast cancer
13 August 2020 - Approval is based on results from SOLAR-1, where Piqray in combination with fulvestrant nearly doubled median progression-free ...
Posted by Michael Wonder on 13 Aug 2020
Elusys Therapeutics receives Health Canada approval for Anthim for the treatment of inhalation anthrax
12 August 2020 - Elusys Therapeutics today announced that Health Canada has approved the company's new drug submission for Anthim ...
Posted by Michael Wonder on 12 Aug 2020
Health Canada approves Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy for the treatment of metastatic non-small cell lung cancer
11 August 2020 - CheckMate-9LA trial results demonstrated superior overall survival versus chemotherapy, regardless of PD-L1 expression or tumour histology. ...
Posted by Michael Wonder on 07 Aug 2020
Catalyst Pharmaceuticals’ Firdapse (amifampridine phosphate) receives marketing approval in Canada for patients with LEMS
6 August 2020 - Catalyst Pharmaceuticals today announced that Canada’s national health care regulatory agency, Health Canada, has approved the ...
Posted by Michael Wonder on 04 Aug 2020
Janssen announces Health Canada approval of Darzalex SC, a new subcutaneous formulation for the treatment of patients with multiple myeloma
4 August 2020 - Darzalex SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in ...
Posted by Michael Wonder on 30 Jul 2020
Health Canada Approves Brivlera (brivaracetam) to treat partial-onset seizures in paediatric epilepsy patients
29 July 2020 - Health Canada's approval of Brivlera provides paediatric epilepsy patients with a treatment option which can be initiated ...
Posted by Michael Wonder on 28 Jul 2020
Health Canada grants marketing authorisation with conditions for Gilead's Veklury (remdesivir) for the treatment of coronavirus disease 2019 (COVID-19)
28 July 2020 - Veklury is the first approved treatment option for COVID-19 in Canada. ...
Posted by Michael Wonder on 23 Jul 2020
Spravato (esketamine) nasal spray is available for Canadian patients
22 July 2020 - A new anti-depressant with a novel mechanism of action to treat major depressive disorder in adults. ...
Posted by Michael Wonder on 17 Jul 2020
Xenleta (lefamulin) receives Health Canada approval for treatment of community acquired pneumonia
16 July 2020 - Nabriva Therapeutics announced today that its partner, Sunovion Pharmaceuticals, has received approval from Health Canada to market ...
Posted by Michael Wonder on 09 Jul 2020
Sarclisa (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma
8 July 2020 - First and only anti-CD38 antibody in combination with pomalidomide and dexamethasone to be approved in Canada. ...
Posted by Michael Wonder on 09 Jul 2020
Astex Pharmaceuticals, Taiho Oncology and Otsuka Pharmaceutical announce Health Canada approval of Inqovi (decitabine and cedazuridine) tablets, oral hypomethylating agent therapy for intermediate and high-risk MDS and C
7 July 2020 - Inqovi is the first orally administered hypomethylating agent approved by the FDA and Health Canada. ...
Posted by Michael Wonder on 23 Jun 2020
Deciphera announces Health Canada’s authorisation of Qinlock (ripretinib) for the treatment of fourth-line gastro-intestinal stromal tumour
22 June 2020 - Qinlock significantly improved progression-free survival and showed clinically meaningful overall survival in global INVICTUS Phase 3 study. ...